Point72 Hong Kong LTD Fate Therapeutics Inc Transaction History

Point72 Hong Kong LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $265,272 - $454,644	12,608 Added 78.53%	28,663 $642,000
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $203,065 - $484,136	11,421 Added 246.46%	16,055 $398,000
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $137,490 - $279,337	4,634 New	4,634 $180,000
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $55,002 - $88,837	-928 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $62,408 - $85,858	928 New	928 $81,000
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $14,292 - $19,035	-470 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $9,498 - $16,558	470 New	470 $16,000
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $2,262 - $3,503	-169 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $1,237 - $1,800	-80 Reduced 32.13%	169 $3,000
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $3,886 - $5,089	249 New	249 $5,000

177

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $126M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.